Literature DB >> 22209993

Interleukin-23 serum levels in patients affected by peripheral arterial disease.

Antonio David1, Salvatore Saitta, Giovanni De Caridi, Filippo Benedetto, Mafalda Massara, Domenica Claudia Risitano, Francesco Saverio Venuti, Francesco Spinelli, Sebastiano Gangemi.   

Abstract

OBJECTIVES: To clarify whether interleukin (IL)-23 is involved in peripheral arterial disease (PAD). DESIGN AND METHODS: We evaluated IL-23 serum levels, in 29 patients suffering from lower extremity PAD and in 30 healthy subjects.
RESULTS: IL-23 serum levels were higher during the three times (T0, T1 and T2) compared to the control group, although only statistically significant for T0 and T2: T0 (15.83 ± 22.08 vs. 8.08 ± 8.62 pg ml, p=0.026), T1 (16.10 ± 23.71 vs. 8.08 ± 8.62 pg/ml, p=0.101), T2 (15.06 ± 16.72 vs. 8.08 ± 8.62 pg/ml, p=0.005).
CONCLUSION: For the first time, our data gives us reason to believe there is an involvement of IL-23 in PAD.
Copyright © 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209993     DOI: 10.1016/j.clinbiochem.2011.12.010

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  8 in total

Review 1.  Anti-inflammatory therapies for atherosclerosis.

Authors:  Magnus Bäck; Göran K Hansson
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

2.  A clinical and proteomics approach to predict the presence of obstructive peripheral arterial disease: From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study.

Authors:  Cian P McCarthy; Nasrien E Ibrahim; Roland R J van Kimmenade; Hanna K Gaggin; Mandy L Simon; Parul Gandhi; Noreen Kelly; Shweta R Motiwala; Renata Mukai; Craig A Magaret; Grady Barnes; Rhonda F Rhyne; Joseph M Garasic; James L Januzzi
Journal:  Clin Cardiol       Date:  2018-06-14       Impact factor: 2.882

3.  Matrix metalloproteinases and risk stratification in patients undergoing surgical revascularisation for critical limb ischaemia.

Authors:  Giovanni De Caridi; Mafalda Massara; Francesco Spinelli; Antonio David; Sebastiano Gangemi; Francesco Fugetto; Raffaele Grande; Lucia Butrico; Roberta Stefanelli; Manuela Colosimo; Stefano de Franciscis; Raffaele Serra
Journal:  Int Wound J       Date:  2015-05-27       Impact factor: 3.315

4.  Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease.

Authors:  Katarzyna Fischer; Hanna Przepiera-Będzak; Marcin Sawicki; Anna Walecka; Iwona Brzosko; Marek Brzosko
Journal:  Mediators Inflamm       Date:  2017-12-21       Impact factor: 4.711

5.  Diacerein inhibits the pro-atherogenic & pro-inflammatory effects of IL-1 on human keratinocytes & endothelial cells.

Authors:  Girish C Mohan; Huayi Zhang; Lei Bao; Benjamin Many; Lawrence S Chan
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

6.  Performance of a clinical/proteomic panel to predict obstructive peripheral artery disease in patients with and without diabetes mellitus.

Authors:  Cian P McCarthy; Shreya Shrestha; Nasrien Ibrahim; Roland R J van Kimmenade; Hanna K Gaggin; Renata Mukai; Craig Magaret; Grady Barnes; Rhonda Rhyne; Joseph M Garasic; James L Januzzi
Journal:  Open Heart       Date:  2019-05-13

Review 7.  The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis.

Authors:  A Egeberg; P Gisondi; J M Carrascosa; R B Warren; U Mrowietz
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-03-15       Impact factor: 6.166

8.  Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes.

Authors:  Sylwia Wasiak; Dean Gilham; Laura M Tsujikawa; Christopher Halliday; Karen Norek; Reena G Patel; Kevin G McLure; Peter R Young; Allan Gordon; Ewelina Kulikowski; Jan Johansson; Michael Sweeney; Norman C Wong
Journal:  Data Brief       Date:  2016-07-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.